Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen – eine randomisierte kontrollierte Studie
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Objective The aim of this study was to investigate the efficacy and efficiency of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain. Of major interest were the evaluation of the influence the treatment had on pain and on quality of life as well as the subjective assessment of positive effects and side effects by the study participants. Methods The placebo-controlled double-blinded pilot study was divided into a 14 week cross-over period (two 4 week medication phases plus wash-out phases) followed by a 16 week medication switch period with free choice of the study drugs (drug A and drug B) by the study participants. The principal inclusion criterion was chronic therapy-resistant pain in causal relationship with a pathologic status of the skeletal and locomotor system. The study participants chose the dosage of the study drug themselves (between 1 und 4 capsules/day, in the case of nabilone this corresponds to (1/4)-1 mg/day). Pain intensity was assessed by a visual analogue scale (VAS), quality of life by the Mezzich and Cohen QOL-score. Results Altogether, 30 patients were included and analyzed. From the results, it is obvious that throughout the cross-over periods the nabilone treatment was superior (medians [25%-; 75%-percentiles]: nabilone/placebo): decrease of the average spinal pain intensity within the last 4 weeks (DeltaVAS) 0.9 [0.0; 2.0] / 0.5 [0.0; 1.7], decrease of the current spinal pain intensity (DeltaVAS) 0.6 [0.0; 2…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These processes have a number of characteristics in common with chronic neuropathic pain or fibromyalgia, chronic conditions for which nabilone has been tested with encouraging results [15–17].”
From Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial (2012) · cites this paper as [15]
In the citing paper
“Benefits of an add-on treatment with nabilone have nonetheless been noted in patients with chronic therapy-resistant pain (observed in causal relationship with a pathological status of the skeletal and locomotor system).167”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [167]
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“CB 2-Rezeptoren werden darüber hinaus insbesondere von Immunzellen (Leukozyten, Milz, Tonsillen) exprimiert [4, 5].”
Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain
Wager, T. D., Rilling, J. K., Smith, E. E., Sokolik, A., Casey, K. L., Davidson, R. J., Kosslyn, S. M., Rose, R. M., & Cohen, J. D. (2004) · Science · doi:10.1126/science.1093065 · Cited by 1,992 · cited 2×
“10% der Studienteilnehmer handelt, was durch die bei Schmerzpatienten bekannte Empfänglichkeit für Placeboeffekte gut erklärbar ist [23].”
BackgroundPharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470 · cited 3×
“CB 2-Rezeptoren werden darüber hinaus insbesondere von Immunzellen (Leukozyten, Milz, Tonsillen) exprimiert [4, 5].”
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827 · cited 1×
“Vergleicht man die Ergebnisse der gegenständlichen Studie mit denen der derzeit aussagekräftigsten doppelblinden placebokontrollierten Studie mit Cannabis bei 667 randomisierten MS-Patienten zur Behandlung der MS-bedingten Symptome Schmerz und Spastizität (CAMS-Studie) [25], so lassen sich durchaus Übereinstimmungen f…”
BackgroundCannabinoids as Therapeutic Agents
(2019) · Chapman & Hall/CRC eBooks · doi:10.1201/9780429260667 · Cited by 311
Cannabinoids in Clinical Practice
Williamson, E. M., & Evans, F. J. (2000) · Drugs · doi:10.2165/00003495-200060060-00005 · Cited by 283
Azad, S. C., Eder, M., Marsicano, G., Lutz, B., Zieglgänsberger, W., & Rammes, G. (2003) · Learning & Memory · doi:10.1101/lm.53303 · Cited by 220 · cited 1×
“Darüber hinaus gibt es Daten zur antispastischen und analgetischen Wirksamkeit von Cannabinoiden insgesamt und Nabilone im Speziellen, die auf eine indirekte Aktivierung von gabaergen Neuronen im Zentralnervensystem, besonders im Rückenmark, und die Beeinflussung dopaminerger Neurone zurück zu führen sein dürfte [11–1…”
BackgroundConti, S., Costa, B., Colleoni, M., Parolaro, D., & Giagnoni, G. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704466 · Cited by 190 · cited 1×
“Diese bekannten physiologischen Einflüsse des Cannabinoidsystems bilden eine plausible Grundlage für klinische Wirkungen auf verschiedene Schmerzformen, wie neuropathischer Schmerz [16], Pruritus [17], Schmerz und Muskelverkrampfung bei Multipler Sklerose (MS) [14], Migräne, Kopfschmerz und Schmerzen am Bewegungsappar…”
BackgroundCannabinoids and multiple sclerosis
Pertwee, R. G. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00255-3 · Cited by 181
Cannabinoids and Multiple Sclerosis
Pertwee, R. G. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0005-2 · Cited by 142 · cited 1×
“Diese bekannten physiologischen Einflüsse des Cannabinoidsystems bilden eine plausible Grundlage für klinische Wirkungen auf verschiedene Schmerzformen, wie neuropathischer Schmerz [16], Pruritus [17], Schmerz und Muskelverkrampfung bei Multipler Sklerose (MS) [14], Migräne, Kopfschmerz und Schmerzen am Bewegungsappar…”
Background
Research works printed but not linked: 1
- Grotenhermer F (2001) Pharmakologie, Toxikologie und therapeutisches Potential von Cannabis und Cannabinoiden. Huber, Bern
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
New Insights into the Placebo and Nocebo Responses
Enck, P., Benedetti, F., & Schedlowski, M. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.030 · Cited by 531
“The FCP has been used occasionally in optimizing dosage of drugs (Perkins et al., 1997; Pinsger et al., 2006) in clinical trials.”
Hill, K. P. (2015) · JAMA · doi:10.1001/jama.2015.6199 · Cited by 508
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460
Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials
Lynch, M. E., & Campbell, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03970.x · Cited by 397
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
Wang, L., Hong, P. J., May, C., Rehman, Y., Oparin, Y., Hong, C. J., Hong, B. Y., AminiLari, M., Gallo, L., Kaushal, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1034 · Cited by 300
“…effects. the bmj | BMJ 2021;373:n1034 | doi: 10.1136/bmj.n1034 9 Chronic non-cancer pain Zajicek et al 2003 Rog et al 2005 Blake et al 2006 Pinsger et al 2006 Wissel et al 2006 Nurmikko et al 2007 Selvarajah et al 2010 Novotna et al 2011 Zajicek et al 2012 Langford et al 2013 Andresen et…”
BackgroundInfluentialWard, S. J., McAllister, S. D., Kawamura, R., Murase, R., Neelakantan, H., & Walker, E. A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12439 · Cited by 276
“In humans, several studies have demonstrated anti-neuropathic effects of whole cannabis, Δ9-tetrahydrocannabinol (THC), or its synthetic analogues nabilone or dronabinol (Pinsger et al., 2006; Skrabek et al., 2008; Ware et al., 2010).”
BackgroundBaron, E. P. (2018) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 251
“The 15 studies that showed positive outcomes included neuropathic pain, fibromyalgia,(122) rheumatoid arthritis,(105) and mixed chronic pain.(104,110,111,118,119,123,124) There was an additional study included in this review that evaluated oromucosal cannabis extracts in central neuropathic pain from brachial plexus r…”
BackgroundSystematic Review and Meta-analysis of Cannabis Treatment for Chronic Pain
Martín-Sánchez, E., Furukawa, T. A., Taylor, J., & Martin, J. L. R. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00703.x · Cited by 225
Häuser, W., Finn, D. P., Kalso, E., Krcevski‐Skvarc, N., Kress, H., Morlion, B., Perrot, S., Schäfer, M., Wells, C., & Brill, S. (2018) · European Journal of Pain · doi:10.1002/ejp.1297 · Cited by 199
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Baron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0862-2 · Cited by 177
Fitzcharles, M., Baerwald, C., Ablin, J. N., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0084-3 · Cited by 178
Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline
Busse, J. W., Vankrunkelsven, P., Zeng, L., Heen, A. F., Merglen, A., Campbell, F. A., Granan, L., Aertgeerts, B., Buchbinder, R., Coen, M., et al. (2021) · BMJ · doi:10.1136/bmj.n2040 · Cited by 198
Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain
Lucas, P. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.684624 · Cited by 131
“A study by Pinsger (2006 ) on the effects of nabilone (a synthetic cannabinoid) as an adjunct to existing chronic pain therapy resulted in reduced pain and improved quality of life.”
BackgroundReview on clinical studies with cannabis and cannabinoids 2005-2009
Hazekamp, A., & Grotenhermen, F. (2010) · Cited by 122
Pini, L. A., Guerzoni, S., Cainazzo, M. M., Ferrari, A., Sarchielli, P., Tiraferri, I., Ciccarese, M., & Zappaterra, M. (2012) · The Journal of Headache and Pain · doi:10.1007/s10194-012-0490-1 · Cited by 107
Effects of cannabis on cognitive function in patients with multiple sclerosis
Honarmand, K., Tierney, M. C., O'Connor, P., & Feinstein, A. (2011) · Neurology · doi:10.1212/wnl.0b013e318212ab0c · Cited by 99
Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity
Karst, M., Wippermann, S., & Ahrens, J. (2010) · Drugs · doi:10.2165/11585260-000000000-00000 · Cited by 105
The Pharmacology and Therapeutic Potential of Plant Cannabinoids
Cascio, M. G., Pertwee, R. G., & Marini, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-54564-6_9 · Cited by 99
Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain
Davis, M. P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.1.85 · Cited by 82
Bestard, J. A., & Toth, C. C. (2011) · Pain Practice · doi:10.1111/j.1533-2500.2010.00427.x · Cited by 76
Medicinal Uses of Marijuana and Cannabinoids
Grotenhermen, F., & Müller‐Vahl, K. (2016) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2016.1265360 · Cited by 88
Nabilone for the Management of Pain
Tsang, C. C., & Giudice, M. G. (2016) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1709 · Cited by 73
Cannabis and pain: a scoping review
Pantoja‐Ruiz, C., Restrepo-Jiménez, P., Castañeda‐Cardona, C., Ferreirós, A., & Rosselli, D. (2021) · Brazilian Journal of Anesthesiology (English Edition) · doi:10.1016/j.bjane.2021.06.018 · Cited by 93
Aggarwal, S. K. (2013) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31824c5e4c · Cited by 62
Jeddi, H. M., Busse, J. W., Sadeghirad, B., Levine, M., Zoratti, M. J., Wang, L., Noori, A., Couban, R., & Tarride, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2022-068182 · Cited by 69
Campbell, G., Stockings, E., & Nielsen, S. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0960-9 · Cited by 58
The central cannabinoid receptor type-2 (CB2) and chronic pain
Shang, Y.-C., & Tang, Y. (2016) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1257992 · Cited by 60
Heng, M. M., McTague, M. F., Lucas, R. C., Harris, M. B., Vrahas, M. S., & Weaver, M. J. (2017) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001002 · Cited by 46
Spanagel, R., & Bilbao, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108680 · Cited by 43
Zhuang, J., Mei, H., Fang, F., & Ma, X. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.937004 · Cited by 49
Reassessment of the role of cannabinoids in the management of pain
Beaulieu, P., & Ware, M. (2007) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e3282efd175 · Cited by 34
Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain
Fitzcharles, M., Petzke, F. W., Tölle, T. R., & Häuser, W. (2021) · Drugs · doi:10.1007/s40265-021-01602-1 · Cited by 40
Ghovanloo, M., Estación, M., Higerd‐Rusli, G. P., Zhao, P., Dib‐Hajj, S. D., & Waxman, S. G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15833 · Cited by 38
Re-Branding Cannabis: The Next Generation of Chronic Pain Medicine?
Carter, G. T., Javaher, S. P., Nguyen, M. H. V., Garrett, S. B., & Carlini, B. H. (2014) · Pain Management · doi:10.2217/pmt.14.49 · Cited by 37
Demes, J. S., McNair, B., & Taylor, M. R. G. (2020) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61837 · Cited by 30
“This is consistent with prior research which showed marijuana led to a significant reduction in chronic pain symptoms (Blake, Robson, Ho, Jubb, & McCabe, 2006; Hill, 2015; Pinsger et al., 2006; Skrabek, Galimova, Ethans, & Perry, 2008; Wissel et al., 2006).”
ResultThe role of cannabinoids in pain control: the good, the bad, and the ugly
Pergolizzi, J. V., LeQuang, J. A., Taylor, R., Raffa, R. B., & Colucci, D. R. (2018) · Minerva Anestesiologica · doi:10.23736/s0375-9393.18.12287-5 · Cited by 33
Cannabinoids in the treatment of rheumatic diseases: Pros and cons.
Sarzi-Puttini, P., Ablin, J., Trabelsi, A., Fitzcharles, M., Marotto, D., & Häuser, W. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102409 · Cited by 23
Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective
Karst, M., & Wippermann, S. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802691951 · Cited by 29
The Efficacy of Cannabis in Reducing Back Pain: A Systematic Review
Price, R. L., Charlot, K. V., Frieler, S., Dettori, J. R., Oskouian, R. J., & Chapman, J. R. (2022) · Global Spine Journal · doi:10.1177/21925682211065411 · Cited by 21
Using cannabinoids in pain and palliative care
Peat, S. (2010) · International Journal of Palliative Nursing · doi:10.12968/ijpn.2010.16.10.79211 · Cited by 21
Role of Cannabinoids in the Management of Neuropathic Pain
Fontelles, M. I. M., & Goicoechea, C. (2008) · CNS Drugs · doi:10.2165/00023210-200822080-00003 · Cited by 23
Tetrahydrocannabinol and Cannabidiol for Pain Treatment—An Update on the Evidence
Safi, K., Sobieraj, J., Błaszkiewicz, M., Żyła, J., Salata, B., & Dzierżanowski, T. (2024) · Biomedicines · doi:10.3390/biomedicines12020307 · Cited by 27
“Additionally, emotional functioning was not improved with medical cannabis compared to placebo [4,88–93].”
BackgroundNabilone for the Treatment of Paraneoplastic Night Sweats: A Report of Four Cases
Maida, V. (2008) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.9880 · Cited by 18
The Pharmacotherapy of Chronic Pain
Lynch, M. E. (2008) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2008.04.001 · Cited by 18
Cremer-Schaeffer, P., Schmidt‐Wolf, G., & Broich, K. (2019) · Der Schmerz · doi:10.1007/s00482-019-00399-z · Cited by 18
Mohiuddin, M. M., Mizubuti, G. B., Haroutounian, S., Smith, S. M., Rice, A. S. C., Campbell, F. A., Park, R., & Gilron, I. (2020) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000807 · Cited by 16
Ghovanloo, M., Dib‐Hajj, S. D., Goodchild, S. J., Ruben, P. C., & Waxman, S. G. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1066455 · Cited by 22
“Similar to CBD, THC has been shown to possess anticonvulsant properties in animal models; however, the noted psychotropic effects of this compound make it a less than ideal therapeutic candidate (Lynch et al., 2004; Pinsger et al., 2006; Russo and Guy, 2006; Mechoulam et al., 2007; Skrabek et al., 2008; Johnson et al.…”
BackgroundGhovanloo, M., Effraim, P. R., Tyagi, S., Zhao, P., Dib‐Hajj, S. D., & Waxman, S. G. (2024) · Communications Biology · doi:10.1038/s42003-024-05781-x · Cited by 16
The State of Synthetic Cannabinoid Medications for the Treatment of Pain
Maglaviceanu, A., Peer, M., Rockel, J. S., Bonin, R. P., Fitzcharles, M., Ladha, K. S., Bhatia, A., Leroux, T. S., Kotra, L. P., Kapoor, M., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01098-9 · Cited by 17
Straube, S., Werny, B., & Friede, T. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.04.006 · Cited by 13
Tavhare, S. D., Acharya, R., Reddy, R. G., & Dhiman, K. S. (2019) · AYU (An International Quarterly Journal of Research in Ayurveda) · doi:10.4103/ayu.ayu_43_19 · Cited by 14
Recent advances in the pharmaceutical management of pain
Hill, L., & Schug, S. A. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.25 · Cited by 10
Balter, R. E., & Haney, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00099-5 · Cited by 12
Cys-loop receptors on cannabinoids: All high?
Schmiedhofer, P. B., Vogel, F. D., Koniuszewski, F., & Ernst, M. C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1044575 · Cited by 10
“Furthermore, using synthetic cannabinoids as add-on therapy (Pinsger et al., 2006; Wissel et al., 2006) or alone (Karst et al.”
MethodThe use of cannabinoids in chronic pain
Reynolds, T. D., & Osborn, H. L. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-010417 · Cited by 11
The Cannabinoid Pharmacology of Bone Healing: Developments in Fusion Medicine
Urreola, G., Le, M. N., Harris, A., Castillo, J. A., Saiz, A. M., Shahzad, H., Martin, A. R., Kim, K. D., Khan, S. N., & Price, R. L. (2025) · Biomedicines · doi:10.3390/biomedicines13081891 · Cited by 7
“Similarly, Yassin et al. reported improvements in both pain levels and functional outcomes among 31 patients with fibromyalgia-related back pain who received adjunctive medical cannabis (under physician supervision) alongside standard analgesic therapies [22].”
Scott, C., Hall, S., Zhou, J., & Lehmann, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010227 · Cited by 9
Harrison, N. J., & Simpson, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-69186-8_15 · Cited by 9
Lenk, R., & Likar, R. (2008) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-008-0619-7 · Cited by 7
Therapeutic properties of cannabinoid drugs and marijuana in several disorders: A narrative review
Alvarado, R. N., Dirección General Adjunta de Políticas y Programas contra las Adicciones, C. N. C. L. A., Sánchez, R. M. D. C., Salcedo, V. V., Dirección General de Políticas y Programas contra las Adicciones, C. N. C. L. A., & Departamento de Investigación Clínica, I. N. D. P. R. D. L. F. M. (2017) · Salud Mental · doi:10.17711/sm.0185-3325.2017.014 · Cited by 6
“Pinsger et al., 2006.2 To investigate the efficiency of nabilone on patients with chronic pain.”
BackgroundInfluentialTargeting the endocannabinoid system for the management of low back pain
Hopkins, M. A., McGuire, B. E., & Finn, D. P. (2024) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2024.102438 · Cited by 6
Cannabis-Based Products for Chronic Pain: An Updated Systematic Review
Chou, R., Fu, R., Ahmed, A. Y., & Morasco, B. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-03152 · Cited by 4
Cannabinoids and Neuropathic Pain
Brownjohn, P. W., & Ashto, J. C. (2012) · InTech eBooks · doi:10.5772/36889 · Cited by 4
“Pinsger et al. (Pinsger et al., 2006), and Berlach et al. (Berlach et al., 2006) have both tested whether nabilone can control chronic pain, and found a statistically significant decrease in pain, with side effects generally mild.”
BackgroundCannabinoids for the Treatment of Chronic Pain: A Critical Review of Randomized Controlled Trials
Hassan, S. I. (2018) · Journal of Pain Management & Medicine · doi:10.35248/2684-1320.18.4.131 · Cited by 4
The function of the endocannabinoid system
Cascio, M. G., & Pertwee, R. G. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511706080.004 · Cited by 4
Consider cannabinoids as an individual therapeutic trial in nociplastic pain
Kim, E. S., & Kang, C. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00954-2 · Cited by 2
Wirksamkeit, Verträglichkeit und Sicherheit von medizinischem Cannabis
Hoch, E., Schneider, M., von Keller, R., Bonnet, U., Falkai, P., Hasan, A., Häuser, W., Hinz, B., Jakob, L., Kabisch, J., et al. (2018) · Springer eBooks · doi:10.1007/978-3-662-57291-7_4 · Cited by 2
Cremer-Schaeffer, P., Schmidt‐Wolf, G., & Broich, K. (2019) · Der Schmerz · Cited by 2
Taylor, F. R., Landy, S. H., & Kaniecki, R. G. (2013) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12090 · Cited by 2
Osório, J. H., & Hernandez, C. J. V. (2019) · Biosalud · doi:10.17151/biosa.2019.18.1.2 · Cited by 2
Fitzcharles, M., & Häuser, W. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00130-0 · Cited by 1
McDonagh, M. S., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., & Chou, R. (2021) · doi:10.23970/ahrqepccerplantpain3 · Cited by 1
Cannabis and cannabinoid for pain
Minerbi, A., & Sahar, T. (2022) · Wiley eBooks · doi:10.1002/9781119701170.ch20 · Cited by 1
Likar, R. (2014) · rheuma plus · doi:10.1007/s12688-014-0110-z
ANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA
Santos‐Moriano, P., Fernández‐Arrojo, L., Rodríguez-Colinas, B., & Plou, F. J. (2016)
Arthrose multidimensional behandeln
Pinsger, M. (2017) · Manuelle Medizin · doi:10.1007/s00337-017-0246-8
Self-citationCannabinoide im täglichen Einsatz: Evidenz – Realität – Vision
Pinsger, M. (2019) · Journal für Gynäkologische Endokrinologie/Österreich · doi:10.1007/s41974-019-0090-z
Self-citationCannabinoids in Neurologic Conditions
Gaston, T. E., Szaflarski, J. P., Bowling, A. C., Liu, Y., Seawalt, T., Leehey, M. A., Nelson, E. L., Rajpal, S., Villavicencio, A. T., Bauer, A. M., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-45968-0_10
Is there a need for weed? The role of cannabinoids in managing neuropathic pain
&NA; (2009) · Drugs & Therapy Perspectives · doi:10.2165/0042310-200925040-00004
Approved Cannabinoid Medicines for Therapeutic Use
JAMES, S. P. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108583336.005
When cannabis is used for medicinal purposes: A focus on back pain
O'Regan, A., & Price, R. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89862-1.00036-2
Clinical uses of cannabis and Catha edulis products
Ezzat, S. M., Abdel-Baki, P. M., Ibrahim, R. M., Elezz, D. A., Abdelaziz, M., & Salem, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95927-8.00028-1
Fenton, C., & Fung, S. S.-P. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01197-7
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517185
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517173
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517164
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517176
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517179
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517167
Medical Cannabis as an Opiate Alternative: A Prospective Observational Cohort Study
Caldera, F. E., Caldera, Z., Shofer, F. S., Abramoff, B. A., Lenrow, D. A., Hampton, S. E., Popescu, A., & Dillingham, T. R. (2026) · Cureus · doi:10.7759/cureus.107248
“Additional studies have reported benefits in other chronic pain conditions, including fibromyalgia and spinal cord injury [26-28].”
da Costa-Oliveira, C., Castro, M. D. J., Silvério, L. A. L., Brandão, M. F. B. D. O., Ramos, Y. J., & Mazzola, P. G. (2026) · Cannabis and Cannabinoid Research · doi:10.1177/25785125261490003
Benyamina, A., & Blecha, L. (2012) · Douleur et Analgésie · doi:10.1007/s11724-012-0294-8
Metadata
- Authors
- Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W.
- Affiliations
- Johannes Kepler University of Linz (AT)
- Medical University of Vienna (AT)
- Corresponding author
- Pinsger, Martin
- Venue
- Wiener klinische Wochenschrift
- Published
- 2006-06
- Volume
- 118
- Issue
- 11-12
- Pages
- 327-335
- ISSN
- 0043-5325 (ISSN-L)
- 1613-7671
- OpenAlex
- W1494478174
- Cited by
- 96
- References
- 26
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 14 · 2021: 7 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 3 · 2014: 2 · 2013: 3 · 2012: 6
- FWCI
- 2.51
- Type
- journal article
- Language
- de
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Wiener klinische Wochenschrift (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- chronic pain, adjunctive therapy, treatment-resistant pain, spinal pain, headache, quality of life, pain intensity, adverse effects, crossover design, cost-effectiveness, patient satisfaction, physician satisfaction
- MeSH terms
- Cannabinoids, Chronic Disease, Double-Blind Method, Female, Humans, Male, Middle Aged, Pain, Pain Measurement, Quality of Life, Dronabinol, Anti-Anxiety Agents, Placebo Effect, Treatment Outcome, Chemotherapy, Adjuvant, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.